key: cord-1016317-0ipmswy4
authors: Kim, Ah Young; Jung, Se Yong; Choi, Jae Young; Kim, Gi Beom; Kim, Young-Hwue; Shim, Woo Sup; Kang, I-Seok; Jung, Jo Won
title: Retrospective Multicenter Study of Respiratory Syncytial Virus Prophylaxis in Korean Children with Congenital Heart Diseases
date: 2016-09-28
journal: Korean Circ J
DOI: 10.4070/kcj.2016.46.5.719
sha: 80522e9ca5c69f759fcb3da6fcfdf3523891594e
doc_id: 1016317
cord_uid: 0ipmswy4

BACKGROUND AND OBJECTIVES: We conducted a review of current data on respiratory syncytial virus (RSV) prophylaxis with palivizumab, in Korean children with congenital heart diseases (CHD). In 2009, the Korean guideline for RSV prophylaxis had established up to five shots monthly per RSV season, only for children <1 year of age with hemodynamic significance CHD (HS-CHD). SUBJECTS AND METHODS: During the RSV seasons in 2009-2015, we performed a retrospective review of data for 466 infants with CHD, examined at six centers in Korea. RESULTS: Infants received an average of 3.7±1.9 (range, 1-10) injections during the RSV season. Fifty-seven HS-CHD patients (12.2%) were hospitalized with breakthrough RSV bronchiolitis, with a recurrence in three patients, one year after the initial check-up. Among patients with simple CHD, only five (1.1%) patients received one additional dose postoperatively, as per the limitations set by the Korean guideline. Among the 30 deaths (6.4%), five (1.1%) were attributed to RSV infection; three to simple CHD, one to Tetralogy of Fallot, and one to hypertrophic cardiomyopathy (HCM). Of the three HCM patients that exceeded guidelines for RSV prophylaxis, two (66.6%) were hospitalized, and one died of RSV infection (33.3%). CONCLUSION: In accordance to the Korean guideline, minimal injections of palivizumab were administered to patients having HS-CHD <one year of age during the RSV season; the risk of RSV infection remains significant among children with simple CHD, cardiomyopathy, and children above the age of one year with HS-CHD.

7.3% will die as a result of complications from RSV infection. The mortality rates associated with RSV infection in CHD have been reported significantly higher than in infants without underlying diseases. [7] [8] [9] For the past 10 years, the humanized monoclonal antibody, palivizumab, has been used as prophylaxis for serious RSV infection in high risk infants, and has resulted in a significant reduction in hospitalization rates for children <24 months of age suffering from HS-CHD. 10) Reflecting the global trend, Korean guidelines by the by Korean National Health Insurance Review and Assessment Service, have approved the use of palivizumab in children <1 year of age with HS-CHD since 2009 (Table 1 ). These criteria, as suggested by Feltes et al., 7) 11) have been applied in the recommendation of indicated RSV prophylaxis in many countries, but only up to 2 years of age. This is the first study to evaluate the compliance with the Korean guideline on prophylactic treatment for RSV in pediatric CHD patients. We retrospectively analyzed current data on RSV prophylaxis to determine the prevalence of morbidity in children with CHD in Korea, who developed RSV infection despite receiving prophylaxis as per the Korean guidelines.

We conducted a retrospective, multicenter study at six major tertiary care children's hospitals (Ajou University School of Medicine, Sejong General Hospital, Pucheon, Seoul National University Children's Hospital, Sungkyunkwan University Samsung Medical Center, Seoul, Ulsan University Asan Medical Center and Yonsei University Cardiovascular Center, Korea) during 6-year seasonal period, from 1 st October 2009 to 31 st March 2015. We examined hospital medical records of all children with CHD who had received palivizumab according to the prophylaxis guideline and clinical decision after approval of the Investigated Research Board (AJIRB-MED-MDB-11-351). A total of 466 children with CHD received 1-5 injections of palivizumab (15 mg/kg) by intramuscular injection every 30 days, over one RSV season (October to February). CHD were identified by code based on the 10 th revision of International Classification of Diseases and Related Health Problems (ICD-10).

The Korean guidelines for RSV prophylaxis suggest that children less than 1 year of age with HS-CHD are most likely to benefit from prophylaxis. HS-CHD was defined as uncorrected or palliated cyanotic CHD, or acyanotic CHD associated with documented pulmonary hypertension, and/or a requirement for medication to manage congestive heart failure (CHF).

Information collected for each patient included date of birth, age at first dose, follow up period, gender, structural type of CHD, and the number of palivizumab injections received before and after RSV infection. Additional data reviewed included the time between the actual start of treatment and the recommendation in the national guideline (October or the first month of life, if the child was born during the RSV season). Any underlying diagnoses of chromosomal defects, prematurity and low birth weight and status of cardiovascular surgery undergone, that involved cardiopulmonary bypass, were reviewed.

We also investigated the patients hospitalized for RSV infection despite receiving palivizumab; factors included their age and calendar month at RSV infection, and factors related to infection severity. For infection severity, we reviewed their visit to the emergency department and ICU admissions, hospital and ICU length of stay, oxygen requirements, mechanical ventilation use, and delay of elective operation. According to different types of heart disease, the rate of RSV infection, all-cause and RSV related mortality, and doses of palivizumab were analyzed. RSV infection was confirmed by direct fluorescent antibody staining, culture, or reverse-transcriptase polymerase chain reaction on nasopharyngeal swabs or aspirates according to policy of each center. We noted the number of patients with breakthrough RSV infection and mortality, by comparison to doses of palivizumab prophylaxis according to type of CHD.

Data were entered into the Statistical Package for the Social Sciences (version 18.0, SPSS Inc., Chicago, IL, USA) program and analyzed using descriptive statistics. All continuous variables were analyzed using standard descriptive statistics with mean±standard deviation values. Statistical significance was defined as p<0.05. 

From October 2009 to March 2015, 466 patients received RSV prophylaxis with palivizumab at six major pediatric cardiac centers in Korea. The mean age of patients at the start of prophylaxis was 2.9±2.8 months (range, 0-11.2 months), and the mean follow-up period was 24.3±16.4 months. The male to female ratio was 1.03 (male:female=237:229).

The main indication for RSV prophylaxis in this study was moderate to severe pulmonary hypertension (n=213; 45.7%), followed by cyanotic heart disease (n=196; 42.1%) and CHF requiring medication (n=115; 24.7%). A total of 4 patients (0.9%) (3 with HCM and 1 with mitral stenosis) had received RSV prophylaxis according to the clinician's recommendation, regardless of exclusive criteria of the Korean guideline of RSV prophylaxis for CHD patients.

Co-morbidities other than CHD were found in 127 patients (27.3%): chromosomal anomalies were found in 65 (13.9%), low birth weight baby in 33 (7.1%), and prematurity in 35 patients (7.5%).

Most patients (n=442; 94.8%) underwent either palliative or definitive cardiac surgery before (60.3%) and after (39.7%) the start of palivizumab vaccination. After cardiac surgery that involved cardiopulmonary bypass, 5 (1.1%) patients received one additional dose immediately postoperatively ( Table 2) .

The mean number of received injections was of 3.7±1.9 per patient (range, 1-10). Only 146 patients (31%) received more than five injections following the guidelines, whereas the majority (n=320; 69%) received less than four injections, including 166 patients (36%) who received only one injection ( Fig. 1 ). Among the patients, 7 who had been born prematurely received palivizumab injections until they reached 2 years of age, according to the Korean guideline for prematurity. There were 182 patients (39%) who did not start the first injection of palivizumab at the recommended time -in the first October or the first month of life if the child was born during the RSV season -according to the guideline, with an average delay of 2.7±2.6 months (range, 1-4 months) (Figs. 1, 2, and 3).

Among the 466 patients with CHD during the follow up period, 39% had no respiratory symptoms, 61% had respiratory symptoms. Of the patients having respiratory symptoms, 49% had non-RSV respiratory infections and 12% had RSV infection. Fiftyseven patients (12.2%) were hospitalized with breakthrough RSV bronchiolitis after prophylaxis. Other respiratory virus infections with rhinovirus, parainfluenza virus, influenza virus, adenovirus, metapneumovirus, bocavirus, coronavirus, and Epstein-Barr virus affected 24 patients (42.1%). Prophylactically treated CHD patients (Table 3) . Three patients were hospitalized twice, once before and once after the 1-year-old check-up. Total of 5 patients were diagnosed as RSV infection after the first year follow-up, including these 3 patients.

Comparison of mortality data between RSV infection and doses of palivizumab according to the structural type of CHD, revealed that one-third of the children (n=176; 37.7%) were classified as having shunt lesions with pulmonary hypertension. Among these, 24 patients (13.6%) were diagnosed with RSV infection. There were 7 in-hospital deaths of patients with shunt lesions, 3 of which were related to RSV infection. In the group of 59 patients (12.7%) with univentricular heart defects, there were 9 deaths, but none were treated for RSV infection. In addition, of the 2 deaths reported in this group, 1 was related to RSV infection. During follow-up, all-cause mortality was reported as 30 for this group (6.4%). In 19 patients who died from cardiac issues, 3 deaths were from early postoperative complications; 11 patients died from other morbidities, including 5 patients (1.1%) due to RSV infection (Table 4 ).

The effectiveness of prophylactic palivizumab for prevention of RSV infection in CHD patients was shown by a randomized controlled study in 1998. 7) Palivizumab, a humanized monoclonal antibody against RSV, has been the gold standard for RSV prophylaxis in high risk groups, and recently was shown by a Cochrane metaanalysis to have significantly reduced the hospitalization rate of infected patients. 10) The study showed a 45% relative reduction in RSV hospitalization among high risk children receiving palivizumab (9.7% vs. 5.3%; p=0.003). before the palivizumab era, about more than 10% of all CHD infants required hospital admission for RSV infection and some needed intensive care; however, palivizumab vaccination at the start of RSV season has been proven to reduce the rate of hospitalizations by half (~5%). 7)12) 13) In Korea, according to the biweekly reports from the Korea Centers for Disease Control and Prevention, the seasonal outbreaks of RSV infection occur during the winter months, namely September through March. Almost all children are susceptible to RSV infection until they reach the age of 2 years, and on an average, nearly half will experience two episodes of infection. 2)9) Prior to the palivizumab era (from 2003 to 2006), in a study of 213 patients diagnosed with lower respiratory infection, 45 CHD patients (21.1%) were hospitalized due to RSV infection, 22 (48.9%) were treated in the ICU, 12 (26.7%) required mechanical ventilation, and 2 (4.4%) died; however, no deaths occurred among non-CHD patients. 14) In our study, the rate of mortality related to RSV infection (1.1%) was reduced significantly but was still a threat to infants with HS-CHD even after palivizumab injection, because the monoclonal antibody tends to attenuate but not eradicate RSV disease. 5)9) [15] [16] [17] Moreover, the rate of RSV-associated hospitalization of children <12 months old with HS-CHD who received more than one prophylactic injection was 12.5%, which was relatively higher than in previous reports from other countries (0.46% to 5.3%). 18) One- fourth of the patients were admitted to the ICU with RSV infection, and 3 patients were hospitalized for longer than 4 weeks. This could relate to incomplete vaccination, which would point to a lack of compliance with the guideline, as well as increased testing for RSV. 5)7)11) [19] [20] [21] [22] [23] Many cases started prophylaxis either earlier (n=70, 15%) or later (n=182, 39%) than the recommendation, and it can be argued that delays in identifying patients at risk could have affected the outcome. 23) Monthly injections of up to five injections are recommended once patients start treatment; however, the majority (69%) of patients in this study received less than four, including 36% who received only one injection. Therefore, factors involved in effective prophylactic treatment include ensuring that treatment is initiated at the right time, and that children with CHD are identified and followed up. Missing or delayed injections may lead to increased rates of re-hospitalization, making it essential to adhere to prophylactic guidelines. 24)25) According to many studies that have reported advantages in socio-economic aspects of prophylaxis of RSV infection in CHD patients under the age of 2 years, recommendations from the guidelines of Canada, Japan, Germany, and Austria for the use of palivizumab have included children younger than 24 months of age. 8) In contrast, the Korean guideline has recommend 12 months as the upper age limit. Our study noted that 3 patients were hospitalized with RSV infection after 1 year of age, who were not treated after the recommended age of 12 months.

The majority of CHD patients in this study (35.6%) had shunt lesions with pulmonary hypertension, and 94.8% had undergone corrective surgery. Because the Korean guideline for the use of palivizumab in infants with CHD limits the vaccination to the infants who are receiving medication for congestive heart failure, patients who showed improvement of heart failure after cardiovascular surgery usually had terminated medication, and therefore, were not eligible for additional vaccinations. Moreover, RSV pneumonia is associated with a high risk of postoperative complications. 4)26) 27) In this study, there were 5 deaths related to RSV infection; of these, underlying heart diseases for 3 among the 5 deaths were associated with simple left-right shunt lesion. The American Association of Pediatricians has recommended administration of another injection of palivizumab (15 mg/kg) as soon as possible in postoperative patients because serum palivizumab levels decrease by 58% after cardiopulmonary bypass. 15)16)28) Therefore, it is essential to supplement this guideline, as well as adhere to the existing guideline, ensuring that treatment is started at the right time and that an additional postoperative injection is given immediately. The emphasis should be the identification of children with CHD.

Cardiomyopathies as well as other structural heart diseases are major risk factors for RSV hospitalization in infants with CHD. 20)29)30) Furthermore, in our study, HCM patients were placed into the high risk group with respect to RSV infection because 66.6% (n=2) had contracted RSV infection and 20% (n=1) of all RSVrelated mortality occurred in the HCM group. Stagnant pulmonary flow due to cardiomyopathy results in significantly abnormal hemodynamics with perivascular infiltrates, leading to altered vascular tone and permeability changes in the alveolar-capillary interface, which is further exaggerated by the inflammation caused by RSV. 29) Therefore, the USA, UK, Japan, France, and Austria have adopted the recommendations for infants with cardiomyopathy as co-morbidity. 8) These findings should be taken into consideration when deciding which children should receive prophylaxis.

There were a few of limitations to this study. A recent systematic review of the cost-effectiveness of palivizumab prophylaxis compared with no prophylaxis in infants and young children with CHD showed a favorable trend, but were not addressed in this study. 30) We are also still collecting data for further study of the treatment effect of palivizumab against RSV in a large population, which is warranted.

For CHD patients in Korea, small doses and omitting or delaying palivizumab prophylaxis were found in major pediatric centers during the 2009-2015 RSV seasons. Even though the current data on RSV prophylaxis has been collected for infants with CHD in Korea, the data might actually be helpful for CHD patients if the Korean guideline would be extended to children up to 24 months of age with HS-CHD, including cardiomyopathy, and postoperative CHD patients. We recommend that the guideline should be updated based on the key findings: (i) the risk of hospitalization due to RSV infection remains high among children with CHD, (ii) children with CHD exhibit a higher rate of morbidity despite prophylactic treatment than that reported in recent studies, 11) [18] [19] [20] [21] [22] and (iii) since the RSV season of Korea is not different with that of other countries, the national guideline might be regarded as outdated by international guidelines. 23) In Korean guidelines, the patient group with HCM was not supported financially. Thus, only a few patients with HCM were included because patients who had received palivizumab injection were rare. This is the first and largest study to evaluate compliance according to the Korean guideline for prophylactic treatment, and to determine that morbidity and mortality due to RSV infection is still significant in children with CHD. According to the Korean guidelines, the risk of RSV infection remains significant among children with hemodynamically insignificant CHD, cardiomyopathy, and children above 1 year-old with HS-CHD.

Hospitalization attributable to influenza and other viral respiratory illnesses in Canadian children

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection

Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening

Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease

Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

Respiratory syncytial virus infections in infants and children with congenital heart disease: update on the evidence of prevention with palivizumab

Respiratory syncytial virus infection in children with congenital heart disease: global data and interim results of Korean RSV-CHD survey

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children

A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease

Economic analysis of palivizumab in infants with congenital heart disease

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections

Respiratory syncytial virus infection cases in congenital heart disease patients

Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease

The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations

Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease

Respiratory syncytial virus prophylaxis in children with cardiac disease: a retrospective singlecentre study

Communityacquired respiratory infections in young children with congenital heart diseases in the palivizumab era: the Spanish 4-season civic epidemiologic study

Respiratory syncytial virus immunoprophylaxis in high-risk infants with heart disease

Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 Palivizumab Outcomes Registry

Lanctôt KL; CARESS investigators. CARESS: the Canadian registry of palivizumab

Evaluating national guidelines for the prophylactic treatment of respiratory syncytial virus in children with congenital heart disease

Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry

Compliance with prophylaxis for respiratory syncytial virus infection in a home setting

Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome

Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience

Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection

Use of palivizumab for the prevention of respiratory syncytial virus infections in children with congenital heart disease. Recommendations from the French Paediatric Cardiac Society

Risk factors for respiratory syncytial virus hospitalisation in children with heart disease

This study was supported by Korean Pediatric Cardiology Society in 2011.